A platinum containing complex comprising:
(a) a fluorescent molecule; and
(b) platinum atom conjugated with the fluorescent molecule. The complex of claim 1, wherein the complex is:
(i) a compound of Formula VI:
wherein:
FM is fluorescent molecule optionally conjugated with a –linker-lipid;
R61 and R62 are same or different and selected independently from halogen, alkyl,
amino, alkylamino, dialkylamino, hydroxyl, alkoxy, thiol, thioalkyl, -S(O)(R63)2,
O-acyl, or any combinations thereof, or R61 and R62, together with the Pt atom
form an optionally substituted cyclyl or heterocyclyl; and
each R63 is independently a C1-C6alkyl;
a compound of Formula VII:
wherein:
FM is fluorescent molecule optionally conjugated with a –linker-lipid; and
p is 0, 1, 2, 3 or 4;
a compound of Formula VIII:

wherein:
FM is fluorescent molecule optionally conjugated with a –linker-lipid; and
t is 0, 1, 2, 3 or 4;
iv) a compound of Formula IX:
wherein:
FM is fluorescent molecule optionally conjugated with a –linker-lipid;
R91 and R92 are hydrogen or together form a carbonyl; and
q is 0, 1, 2, 3 or 4;
a compound of Formula X:
wherein:
FM is fluorescent molecule optionally conjugated with a –linker-lipid;
R101 is H or a –linker-lipid;
b is 1, 2, 3 or 4; and

wherein:
each FM is an independently selected fluorescent molecule optionally conjugated
with a –linker-lipid.
The complex of claim 2, wherein the fluorescent molecule is selected from the group
consisting of:
(i) a compound of Formula V:
wherein Y is O, S or NR53; Z is O or NR53; R51 is absent, alkoxy, optionally substituted amino, thiol, optionally substituted alkylthio, –linker-(anti-cancer agent), –linker-carbohydrate or –linker-lipid; R52 is H, alkyl, cyclyl, heterocyclyl, aryl, heteroaryl, or –linker-lipid; and each R53 is same or different and selected independently from the group consisting of alkyl, cyclyl, heterocyclyl, aryl, heteroaryl, optionally substituted PEG, –linker-carbohydrate, –linker-(anti-cancer

wherein R11 is hydrogen, alkoxy, optionally substituted alkylamino, optionally
substituted alkylthio, –linker-(anti-cancer agent), –linker-carbohydrate, or –linker
-lipid;
a compound of Formula II:
wherein R21 is Hydrogen, alkyl, cyclyl, heterocyclyl, aryl, heteroaryl, optionally
substituted PEG, –linker-carbohydrate, –linker-(anti-cancer agent), –linker-
linker-lipid, each of which can be optionally substituted; a compound of Formula III:
wherein R31 and R32 are same or different and selected independently from the group consisting of hydrogen, alkyl, cyclyl, heterocyclyl, aryl, heteroaryl, or – linker-lipid, each of which can be optionally substituted; and a compound a Formula IV;

wherein X is O or NR43; R41 is absent, hydroxyl, alkoxy, –linker-lipid or polyethylene glycol; R42 is H, alkyl, cyclyl, heterocyclyl, aryl or heteroaryl; and R43 is H, alkyl, cyclyl, heterocyclyl, aryl or heteroaryl, each of which can be optionally substituted.
The complex of claim 3, wherein the fluorescent molecule is:
(i) a compound of Formula V’:
a compound of Formula I’:
wherein R11 is hydrogen, alkoxy, alkylamino, alkylthio, –linker-carbohydrate, or –
linker-lipid;
a compound of Formula II’:
wherein R21 is H, optionally substituted alkyl, optionally substituted PEG, – linker-carbohydrate, –linker-(anti-cancer agent), –linker-NH(CH2CO2H)2, -linker-

wherein R31 and R32 are same or different and independently H, optionally
substituted alkyl, or –linker-lipid; or
(v) a compound of Formula IV’:
The complex of any of claims 1-4, wherein the the fluorescent molecule is conjugated
with a lipid.
The complex of any of claims 1-4, wherein the the fluorescent molecule is of Formula I”:
wherein R11 is hydrogen, alkoxy, alkylamino, alkylthio, –linker-(anti-cancer agent), –
linker-carbohydrate, or –linker-lipid.
The complex of any of claims 1-4, wherein the the fluorescent molecule is of Formula II”:
wherein R21 is a optionally substituted PEG, –linker-carbohydrate, –linker-(anti-cancer
linker-lipid.
8. The complex of any of claims 1-4, wherein the the fluorescent molecule is of Formula
III”:

wherein at least one of R31 and R32 is a –linker-lipid. The complex of any of claims 1-4, wherein: (i) the fluorescent molecule is of Formula V”:
wherein:
each X is same or different and selected independently from the group consisting of O, N,
S, NH and NR
each R’ is same or different and selected independently from the group consisting of H,
alkyl, cyclyl, heterocyclyl, aryl and heteroaryl, each of which can be optionally
substituted; and
R is alkyl, cyclyl, heterocyclyl, aryl or heteroaryl, each of which can be optionally
substituted; or
(ii) the fluorescent molecule is of Formula V”-B:
wherein:
Z is alkoxy, alkylamino, alkylthio or –E-linker-carbohydrate; E is O, NH or S;
each X is same or different and selected independently from the group consisting of O, N, S, NH and NR
each R’ is same or different and selected independently from the group consisting of H, alkyl, cyclyl, heterocyclyl, aryl and heteroaryl, each of which can be optionally substituted; and
R is alkyl, cyclyl, heterocyclyl, aryl or heteroaryl, each of which can be optionally
substituted.
. The complex of any of claims 1-4, wherein:
(i) the fluorescent molecule is of Formula V’”:

wherein:
E is NH or S;
X is O or NR; and
R is H, alkyl, cyclyl, heterocyclyl, aryl or heteroaryl, each of which can be optionally
substituted; or
(ii) the fluorescent molecule is of Formula V’”-B:
wherein:
E is NH or S;
R’ is optionally substituted PEG, –linker-carbohydrate, –linker-(anti-cancer agent), –
linker-NH(CH2CO2)2, -linker-CO2, NH2, or C°2;
X is O or NR; and
R is H, alkyl, cyclyl, heterocyclyl, aryl or heteroaryl, each of which can be optionally
substituted.
The complex of any of claims 1-10, wherein the platinum atom is conjugated to rest of
the compound via a covalent bond, coordinate bond or a combination thereof.
The complex of claim 11, wherein the platinum atom is conjugated to rest of the
compound via a O->Pt or N->Pt coordination bond.
The complex of any of claims 1-10, wherein the platinum atom is conjugated to
fluorescent molecule via at least one coordination bond.
The complex of claim 13, wherein the platinum atom is conjugated to fluorescent
molecule O->Pt or N->Pt coordination bond.
The complex of any of claims 1-4, wherein the complex is selected from the group
consisting of:

where X is O or N; R’ is H or optionally substituted alkyl; and R is cholesterol, lumisterol, alpha-tocopherol or vitamin A.
The complex of any of claims 14-27, wherein the complex is selected from the group consisting of:

The complex of any of claims 1-22, wherein the compound has increased cellular uptake
of platinum relative to cisplatin or oxaliplatin in cancer cells.
The complex of any of claims 1-23, wherein the compound has a higher accumulation of
platinum in a tumor relative to cisplatin or oxaliplatin at an equivalent dosage amount of
amount of cisplatin or oxaliplatin.
A compound of Formula IV:
wherein:
X is O or NR43;
R41 is H, hydroxyl, alkoxy, –linker-lipid or polyethylene glycol;

CLE
R42 is H, alkyl, cyclyl, heterocyclyl, aryl or heteroaryl;
R43 is H, alkyl, cyclyl, heterocyclyl, aryl or heteroaryl, and
wherein in R41, R42 and R43 can be optionally substituted.
The compound of claim 25, wherein the compound is of Formula IV’:
wherein:
Y is O, S or NR53; Z is O or NR53;
R51 is H, alkoxy, optionally substituted alkylamino, optionally substituted alkylthio, – linker-carbohydrate, –linker-(anti-cancer agent) or –linker-lipid;
R52 is H, alkyl, cyclyl, heterocyclyl, aryl, heteroaryl, optionally substituted PEG, –linker-carbohydrate, –linker-(anti-cancer agent), –linker-NH(CH2CO2H)2, -linker-CO2H,
each R53 is same or different and selected independently from the group consisting of alkyl, cyclyl, heterocyclyl, aryl, heteroaryl, or –linker-lipid,
provided that at least one of R51 and R52 is –linker-lipid, –linker-(anti-cancer agent), or – linker-carbohydrate, or R52 is optionally substituted PEG, –linker-NH(CH2CO2H)2, -
wherein in R51, R52 and R53 can be optionally substituted.
The compound of claim 27, wherein the compound is of Formula V’:

The compound of claim 28, wherein: (i) the compound is of Formula V”:
wherein:
each X is same or different and selected independently from the group consisting of O, N,
S, NH and NR
each R’ is same or different and selected independently from the group consisting of H,
alkyl, cyclyl, heterocyclyl, aryl and heteroaryl; and
R is alkyl, cyclyl, heterocyclyl, aryl or heteroaryl, and
wherein in R’ and R can be optionally substituted; or
(ii) the compound of is of Formula V”-B:
wherein:
Z is –E-linker-(anti-cancer agent) or –E-linker-carbohydrate;
E is O, NH or S;
each X is same or different and selected independently from the group consisting of O, N,
S, NH and NR
each R’ is same or different and selected independently from the group consisting of H,
alkyl, cyclyl, heterocyclyl, aryl and heteroaryl, each of which can be optionally
substituted; and
R is alkyl, cyclyl, heterocyclyl, aryl or heteroaryl, each of which can be optionally
substituted.
The compound of claim 28, wherein:

wherein:
E is NH or S;
X is O or NR; and
R is H, alkyl, cyclyl, heterocyclyl, aryl or heteroaryl, each of which can be optionally
substituted; or
(ii) the compound is of Formula V’”-B:
wherein:
E is NH or S;
R’ is optionally substituted PEG, -linker-carbohydrate, -linker-(anti-cancer agent),
linker-NH(CH2CO2H)2, -linker-CO2H, Nn2, or ou2n ;
X is O or NR; and
R is H, alkyl, cyclyl, heterocyclyl, aryl or heteroaryl, each of which can be optionally substituted.
wherein R11 is a –linker-carbohydrate or –linker-lipid. A compound of Formula II”:

wherein R31 and R32 are same or different and selected independently from the group
consisting of hydrogen, alkyl, cyclyl, heterocyclyl, aryl, heteroaryl, or –linker-lipid, each
of which can be optionally substituted, provided that at least one of R31 and R32 is a –
linker-lipid.
The compound of any of claims 25-33, wherein the wherein the lipid is selected from fats,
waxes, sterols, steroids, bile acids, fat-soluble vitamins, monoglycerides, diglycerides,
phospholipids, glycolipids, sulpholipids, aminolipids, chromolipids,
glycerophospholipids, sphingolipids, prenol lipids, saccharolipids, polyketides and fatty
acids or any combination thereof, preferably sterols selected from cholesterol, cholesterol
chloroformate or derivatives thereof, and any combination thereof.
The compound of claim 34, wherein the lipid is cholesterol; lumisterol, alpha-tocopherol
or vitamin A.
The compound of any of claims 25-35, wherein the linker is selected from the group
consisting of a bond, —(CH2)n—, —(CH2)nO—, —O(CH2)nO—, —(CH2)nNH—, —
O(CH2)nNH—, —NH(CH2)nNH—, —OCH2(CH2)nC(O)—; —C(O)(CH2)nC(O)—; —
(CH2)nNHC(O)O—, —(CH2)nOC(O)NH—, — (CH2)nC(O)NH(CH2)mO—, —
(CH2)nO(CH2)mO—, — (CH2)nO(O)—, —(CH2)nNHC(O)(CH2)mO—, —(CH2)nC(O)O—
; or —OC(O)(CH2)nC(O)O—; wherein n and m are independently 0, 1, 2, 3, 4, or 5

The compound of claim 36, wherein the linker is –CH2CH2-.
A nanoparticle comprising a complex of any of claims 1-24 or a compound of any of claims 25-37.
The nanoparticle of claim 38, wherein the nanoparticle further comprises a co-lipid. The nanoparticle of claim 38 or 39, wherein the nanoparticle further comprises a stabilizer.
The nanoparticle of any of claims 38-40, wherein the nanoparticle comprises Soy-
phosphatidyl choline and 1,2-Distearoyl-sn-Glycero-3-Phosphoethalonamine-N-
[Methoxy(Polyethylene glycol)-2000] as co-lipids.
A pharmaceutical composition comprising a nanoparticle of any of claims 36-41 and a pharmaceutically acceptable excipient or carrier.
A pharmaceutical composition comprising or a complex of any of claims 1-24 or a compound of any of claims 25-37 and a pharmaceutically acceptable excipient or carrier. The pharmaceutical composition of claim 42 or 43, wherein the excipient is selected from a group comprising granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, glidants, anti-adherents, anti-static agents, surfactants, anti-oxidants, gums, coating agents, coloring agents, flavouring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents, plant cellulosic material, spheronization agents, and any combination thereof.
The pharmaceutical composition of any of claims 42-44, wherein the composition is formulated into a dosage form selected from the group consisting of injectable, tablet, lyophilized powder, liposomal suspension, and any combinations thereof.